Form 4: Amylyx Pharmaceuticals Director Acquires Stock Options

Bernhardt G. Zeiher, a Director at Amylyx Pharmaceuticals, Inc., acquired 24,372 stock options on June 4, 2026, with an exercise price of $14.31.

Summary

• Bernhardt G. Zeiher, a Director at Amylyx Pharmaceuticals, Inc. (AMLX), acquired 24,372 stock options on June 4, 2026.
• The options have an exercise price of $14.31 per share.
• These options are exercisable and will vest in full on the earlier of June 4, 2027, or the date of the next annual meeting, provided Zeiher remains in continuous service to the company.
• Following this transaction, Zeiher beneficially owns 24,372 shares of common stock through these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction (option grant) rather than a significant financial event or strategic shift.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule ties the full realization of the option value to continued service and a specific future date, aligning the director's interests with long-term company performance.

Negatives

• The filing only details the acquisition of options, not the exercise or sale of shares, so immediate financial impact is not yet realized.
• The exercise price of $14.31 is a key reference point for future profitability on these options.

Risks

• The value of the acquired options is contingent on the future stock price of Amylyx Pharmaceuticals exceeding the exercise price of $14.31.
• The vesting of options is subject to the reporting person's continuous service, implying a risk of forfeiture if service is terminated before vesting.

Future Outlook

The future outlook for the acquired options depends on Amylyx Pharmaceuticals' stock performance. The options are set to expire on June 3, 2036, and will fully vest by June 4, 2027, or the next annual meeting, contingent on the reporting person's continued employment.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the pharmaceutical and biotechnology sectors, often used as a long-term incentive to align executive interests with shareholder value. The specific exercise price and vesting schedule are critical factors in evaluating the potential upside for the executive and the company's future performance expectations.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be seen as a positive signal of management's commitment, but the direct impact on share price is minimal unless the options are exercised and the stock price increases significantly.

Next Steps

• The reporting person must maintain continuous service to Amylyx Pharmaceuticals through the vesting dates.
• The options can be exercised at any time after vesting and before expiration, provided the stock price is above the exercise price.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, Insider Trading